Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for Mediators of Inflammation, enter your email address in the box below.

Mediators of Inflammation
Volume 2017 (2017), Article ID 9467819, 9 pages
https://doi.org/10.1155/2017/9467819
Research Article

Persistent Unresolved Inflammation in the Mecp2-308 Female Mutated Mouse Model of Rett Syndrome

Alessio Cortelazzo,1,2,3 Claudio De Felice,4 Bianca De Filippis,5 Laura Ricceri,5 Giovanni Laviola,5 Silvia Leoncini,1,6 Cinzia Signorini,6 Monica Pescaglini,3 Roberto Guerranti,2,3 Anna Maria Timperio,7 Lello Zolla,7 Lucia Ciccoli,6 and Joussef Hayek1

1Child Neuropsychiatry Unit, University Hospital Azienda Ospedaliera Universitaria Senese (AOUS), Viale M. Bracci 16, 53100 Siena, Italy
2Department of Medical Biotechnologies, University of Siena, Via A. Moro 2, 53100 Siena, Italy
3Clinical Pathology Laboratory Unit, University Hospital AOUS, Viale M. Bracci 16, 53100 Siena, Italy
4Neonatal Intensive Care Unit, University Hospital AOUS, Viale M. Bracci 16, 53100 Siena, Italy
5Centre for Behavioural Sciences and Mental Health, Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, 00161 Rome, Italy
6Department of Molecular and Developmental Medicine, University of Siena, Via A. Moro 6, 53100 Siena, Italy
7Department of Ecological and Biological Sciences, University of Tuscia, Largo dell’Università, snc, 01100 Viterbo, Italy

Correspondence should be addressed to Alessio Cortelazzo; moc.liamg@elaetroc

Received 6 December 2016; Accepted 19 April 2017; Published 16 May 2017

Academic Editor: Chiara De Luca

Copyright © 2017 Alessio Cortelazzo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Chahrour and H. Y. Zoghbi, “The story of Rett syndrome: from clinic to neurobiology,” Neuron, vol. 56, no. 3, pp. 422–437, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. L. S. Weaving, C. J. Ellaway, J. Gecz, and J. Christodoulou, “Rett syndrome: clinical review and genetic update,” Journal of Medical Genetics, vol. 42, no. 1, pp. 1–7, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Rett, “On a unusual brain atrophy syndrome in hyperammonemia in childhood,” Wiener Medizinische Wochenschrift, vol. 116, no. 37, pp. 723–726, 1966. View at Google Scholar
  4. B. Hagberg, “Clinical manifestations and stages of Rett syndrome,” Mental Retardation and Developmental Disabilities Research Reviews, vol. 8, no. 2, pp. 61–65, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. J. L. Neul, W. E. Kaufmann, D. G. Glaze et al., “Rett syndrome: revised diagnostic criteria and nomenclature,” Annals of Neurology, vol. 68, no. 6, pp. 944–950, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. R. E. Amir, I. B. Van den Veyver, M. Wan, C. Q. Tran, U. Francke, and H. Y. Zoghbi, “Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG binding protein 2,” Nature Genetics, vol. 23, no. 2, pp. 185–188, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Chahrour, S. Y. Jung, C. Shaw et al., “MeCP2, a key contributor to neurological disease, activates and represses transcription,” Science, vol. 320, no. 5880, pp. 1224–1229, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. P. L. Jones, G. J. Veenstra, P. A. Wade et al., “Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription,” Nature Genetics, vol. 19, no. 2, pp. 187–191, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Bienvenu and J. Chelly, “Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized,” Nature Reviews. Genetics, vol. 7, no. 6, pp. 415–426, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Wait, G. Chiesa, C. Parolini et al., “Reference maps of mouse serum acute-phase proteins: changes with LPS-induced inflammation and apolipoprotein A-I and A-II transgenes,” Proteomics, vol. 5, no. 16, pp. 4245–4253, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. D. M. Katz, J. E. Berger-Sweeney, J. H. Eubanks et al., “Preclinical research in Rett syndrome: setting the foundation for translational success,” Disease Models & Mechanisms, vol. 5, no. 6, pp. 733–745, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Z. Chen, S. Akbarian, M. Tudor, and R. Jaenisch, “Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice,” Nature Genetics, vol. 27, no. 3, pp. 327–331, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Moretti, J. A. Bouwknecht, R. Teague, R. Paylor, and H. Y. Zoghbi, “Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome,” Human Molecular Genetics, vol. 14, no. 2, pp. 205–220, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. J. D. Picker, R. Yang, L. Ricceri, and J. Berger-Sweeney, “An altered neonatal behavioral phenotype in Mecp2 mutant mice,” Neuroreport, vol. 17, no. 5, pp. 541–544, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Santos, A. Silva-Fernandes, P. Oliveira, N. Sousa, and P. Maciel, “Evidence for abnormal early development in a mouse model of Rett syndrome,” Genes, Brain, and Behavior, vol. 6, no. 3, pp. 277–286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Shahbazian, J. Young, L. Yuva-Paylor et al., “Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3,” Neuron, vol. 35, no. 2, pp. 243–254, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Ricceri, B. De Filippis, and G. Laviola, “Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches,” Behavioural Pharmacology, vol. 19, no. 5-6, pp. 501–517, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Cortelazzo, C. De Felice, R. Guerranti et al., “Subclinical inflammatory status in Rett syndrome,” Mediators of Inflammation, vol. 2014, Article ID 480980, 13 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. J. C. Cronk, N. C. Derecki, E. Ji et al., “Methyl-CpG binding protein 2 regulates microglia and macrophage gene expression in response to inflammatory stimuli,” Immunity, vol. 42, no. 2, pp. 679–691, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. N. C. Derecki, E. Privman, and J. Kipnis, “Rett syndrome and other autism spectrum disorders-brain diseases of immune malfunction?” Molecular Psychiatry, vol. 15, no. 4, pp. 355–363, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. C. M. O’Driscoll, M. P. Lima, W. E. Kaufmann, and J. P. Bressler, “Methyl CpG binding protein 2 deficiency enhances expression of inflammatory cytokines by sustaining NF-κB signaling in myeloid derived cells,” Journal of Neuroimmunology, vol. 283, pp. 23–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Leoncini, C. De Felice, C. Signorini et al., “Cytokine dysregulation in MECP2- and CDKL5-related Rett syndrome: relationships with aberrant redox homeostasis, inflammation, and ω-3 PUFAs,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 421624, 18 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Horiuchi, L. Smith, I. Maezawa, and L. W. Jin, “CX(3)CR1 ablation ameliorates motor and respiratory dysfunctions and improves survival of a Rett syndrome mouse model,” Brain, Behavior, and Immunity, vol. 60, pp. 106–116, 2017. View at Publisher · View at Google Scholar
  24. C. Cray, J. Zaias, and N. H. Altman, “Acute phase response in animals: a review,” Comparative Medicine, vol. 59, no. 6, pp. 517–526, 2009. View at Google Scholar
  25. N. L. Anderson and N. G. Anderson, “The human plasma proteome: history, character, and diagnostic prospects,” Molecular and Cellular Proteomics, vol. 2, no. 1, p. 50, 2003. View at Publisher · View at Google Scholar
  26. V. Matarazzo and G. V. Ronnett, “Temporal and regional differences in the olfactory proteome as a consequence of MeCP2 deficiency,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 20, pp. 7763–7768, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Cortelazzo, C. De Felice, R. Guerranti et al., “Abnormal N-glycosylation pattern for brain nucleotide pyrophosphatase-5 (NPP-5) in Mecp2-mutant murine models of Rett syndrome,” Neuroscience Research, vol. 105, pp. 28–34, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. B. De Filippis, L. Ricceri, and G. Laviola, “Early postnatal behavioral changes in the Mecp2-308 truncation mouse model of Rett syndrome,” Genes, Brain, and Behavior, vol. 9, no. 2, pp. 213–223, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Lyon, P. W. Burnet, J. N. Kew et al., “Fractionation of spatial memory in GRM2/3 (mGlu2/mGlu3) double knockout mice reveals a role for group II metabotropic glutamate receptors at the interface between arousal and cognition,” Neuropsychopharmacology, vol. 36, no. 13, pp. 2616–2628, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. B. De Filippis, M. Musto, L. Altabella, E. Romano, R. Canese, and G. Laviola, “Deficient purposeful use of forepaws in female mice modelling Rett syndrome,” Neural Plasticity, vol. 2015, Article ID 326184, 13 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Görg, C. Obermaier, G. Boguth et al., “The current state of two-dimensional electrophoresis with immobilized pH gradients,” Electrophoresis, vol. 21, no. 6, pp. 1037–1053, 2000. View at Publisher · View at Google Scholar
  32. M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding,” Analytical Biochemistry, vol. 72, no. 1-2, pp. 248–254, 1976. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Mortz, T. N. Krogh, H. Vorum, and A. Görg, “Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ionization-time of flight analysis,” Proteomics, vol. 1, no. 11, pp. 1359–1363, 2001. View at Publisher · View at Google Scholar
  34. U. Hellman, C. Wernstedt, J. Góñez, and C. H. Heldin, “Improvement of an “In-Gel” digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing,” Analytical Biochemistry, vol. 224, no. 1, pp. 451–455, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Isordia-Salas, R. A. Pixley, I. M. Sáinz, C. Martínez-Murillo, and R. W. Colman, “The role of plasma high molecular weight kininogen in experimental intestinal and systemic inflammation,” Archives of Medical Research, vol. 35, no. 5, pp. 369–377, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. J. M. Hunt and R. Tuder, “Alpha 1 anti-trypsin: one protein, many functions,” Current Molecular Medicine, vol. 12, no. 7, pp. 827–835, 2012. View at Publisher · View at Google Scholar
  37. T. Jinbo, T. Sakamoto, and S. Yamamoto, “Serum α2-macroglobulin and cytokine measurements in an acute inflammation model in rats,” Laboratory Animals, vol. 36, no. 2, pp. 153–157, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. D. A. Loeffler, J. R. Connor, P. L. Juneau et al., “Transferrin and iron in normal Alzheimer’s disease, and Parkinson’s disease brain regions,” Journal of Neurochemistry, vol. 65, no. 2, pp. 710–716, 1995. View at Google Scholar
  39. G. J. Mizejewski, “Alpha-fetoprotein (AFP) and inflammation: is AFP an acute and/or chronic phase reactant?” Journal of Hematology & Thromboembolic Diseases, vol. 3, no. 1, pp. 1–9, 2015. View at Publisher · View at Google Scholar
  40. M. M. Dean, R. M. Minchinton, S. Heatley, and D. P. Eisen, “Mannose binding lectin acute phase activity in patients with severe infection,” Journal of Clinical Immunology, vol. 25, no. 4, pp. 346–352, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. J. P. Nicholson, M. R. Wolmarans, and G. R. Park, “The role of albumin in critical illness,” British Journal of Anaesthesia, vol. 85, no. 4, pp. 599–610, 2000. View at Publisher · View at Google Scholar
  42. D. Nguyen, M. Nickel, C. Mizuguchi, H. Saito, S. Lund-Katz, and M. C. Phillips, “Interactions of apolipoprotein A-I with high-density lipoprotein particles,” Biochemistry, vol. 52, no. 11, pp. 1963–1972, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Yousefzadeh, S. A. Shapses, and X. Wang, “Vitamin D binding protein impact on 25-Hydroxyvitamin D levels under different physiologic and pathologic conditions,” International Journal of Endocrinology, vol. 2014, Article ID 981581, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Sanjurjo, N. Amézaga, C. Vilaplana et al., “The scavenger protein apoptosis inhibitor of macrophages (AIM) potentiates the antimicrobial response against Mycobacterium tuberculosis by enhancing autophagy,” PloS One, vol. 8, no. 11, article e79670, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Sanjurjo, N. Amézaga, G. Aran et al., “The human CD5L/AIM-CD36 axis: a novel autophagy inducer in macrophages that modulates inflammatory responses,” Autophagy, vol. 11, no. 3, pp. 487–502, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Cortelazzo, R. Guerranti, C. De Felice et al., “A plasma proteomic approach in Rett syndrome: classical versus preserved speech variant,” Mediators of Inflammation, vol. 2013, Article ID 438653, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. C. De Felice, A. Cortelazzo, C. Signorini et al., “Effects of ω-3 polyunsaturated fatty acids on plasma proteome in Rett syndrome,” Mediators of Inflammation, vol. 2013, Article ID 723269, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Cortelazzo, C. De Felice, S. Leoncini et al., “Inflammatory protein response in CDKL5-Rett syndrome: evidence of a subclinical smouldering inflammation,” Inflammation Research, vol. 66, no. 3, pp. 269–280, 2017. View at Publisher · View at Google Scholar
  49. I. Haruta, Y. Kato, E. Hashimoto et al., “Association of AIM, a novel apoptosis inhibitory factor, with hepatitis via supporting macrophage survival and enhancing phagocytotic function of macrophages,” The Journal of Biological Chemistry, vol. 276, no. 25, pp. 22910–22914, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Sanjurjo, G. Aran, N. Roher, A. F. Valledor, and M. R. Sarrias, “AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease,” Journal of Leukocyte Biology, vol. 98, no. 2, pp. 173–184, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Díaz de León-Guerrero, G. Pedraza-Alva, and L. Pérez-Martinez, “In sickness and in health: the role of methyl-CpG binding protein 2 in the central nervous system,” The European Journal of Neuroscience, vol. 33, no. 9, pp. 1563–1574, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. B. J. Van Lenten, S. T. Reddy, M. Navab, and A. M. Fogelman, “Understanding changes in high density lipoproteins during the acute phase response,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 8, pp. 1687-1688, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Macco, I. Pelizzoni, A. Consonni et al., “Astrocytes acquire resistance to iron-dependent oxidative stress upon proinflammatory activation,” Journal of Neuroinflammation, vol. 10, no. 1, p. 130, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. C. De Felice, C. Signorini, S. Leoncini et al., “The role of oxidative stress in Rett syndrome: an overview,” Annals of the new York Academy of Sciences, vol. 1259, pp. 121–135, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Signorini, C. De Felice, T. Durand et al., “Isoprostanes and 4-hydroxy-2-nonenal: markers or mediators of disease? Focus on Rett syndrome as a model of autism spectrum disorder,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 343824, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. C. De Felice, F. Della Ragione, C. Signorini et al., “Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome,” Neurobiology of Disease, vol. 68, pp. 66–77, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. C. N. Serhan, S. D. Brain, C. D. Buckley et al., “Resolution of inflammation: state of the art, definitions and terms,” FASEB Journal, vol. 21, no. 2, pp. 325–332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Grillo, C. Lo Rizzo, L. Bianciardi et al., “Revealing the complexity of a monogenic disease: Rett syndrome exome sequencing,” PloS One, vol. 8, no. 2, article e56599, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. N. Kishi and J. D. Macklis, “MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions,” Molecular and Cellular Neurosciences, vol. 27, no. 3, pp. 306–321, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Sugino, C. M. Hempel, B. W. Okaty et al., “Cell-type-specific repression by methyl-CpG-binding protein 2 is biased toward long genes,” The Journal of Neuroscience, vol. 34, no. 38, pp. 12877–12883, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Jain, K. Singh, S. Chirumamilla et al., “Ocular MECP2 protein expression in patients with and without Rett syndrome,” Pediatric Neurology, vol. 43, no. 1, pp. 35–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. M. J. Lyst and A. Bird, “Rett syndrome: a complex disorder with simple roots,” Nature Reviews. Genetics, vol. 16, no. 5, pp. 261–275, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Ruth and A. P. Bird, “MeCP2 mutations: progress towards understanding and treating Rett syndrome,” Genome Medicine, vol. 9, no. 1, p. 7, 2017. View at Publisher · View at Google Scholar
  64. P. D. Ross, J. Guy, J. Selfridge et al., “Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes,” Human Molecular Genetics, vol. 25, no. 20, pp. 4389–4404, 2016. View at Publisher · View at Google Scholar
  65. L. M. Monteggia and E. T. Kavalali, “Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission,” Biological Psychiatry, vol. 65, no. 3, pp. 204–210, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Ehrhart, S. L. Coort, E. Cirillo, E. Smeets, C. T. Evelo, and L. M. Curfs, “Rett syndrome - biological pathways leading from MECP2 to disorder phenotypes,” Orphanet Journal of Rare Diseases, vol. 11, no. 1, p. 158, 2016. View at Publisher · View at Google Scholar · View at Scopus